EHA 2022 Conference Coverage

 

EHA 2022 Conference Coverage
U

EHA 2022 Magrolimab in Combination With Azacitidine for Untreated HR-MDS: 5F9005 Phase 1b Study Results

By EHA 2022 Conference Coverage FEATURING Uwe Platzbecker
By EHA 2022 Conference Coverage FEATURING Uwe Platzbecker
11 views
June 21, 2022
0 Comments
Login to view comments. Click here to Login
MDS and MPN
30
EHA 2022 Conference Coverage

Lecture Summary - EHA 2022 CD47 Targeting in HR-MDS: Surveying Clini…

Feat. D. Sallman
06:24
EHA 2022 Conference Coverage

EHA 2022 CD47 Targeting in HR-MDS: Surveying Clinical Data for Magro…

Feat. D. Sallman
30
EHA 2022 Conference Coverage

[private] Lecture Summary - EHA 2022 on ENHANCE Study: A Randomized …

Feat. D. Sallman
06:24
EHA 2022 Conference Coverage

[private] EHA 2022 on ENHANCE Study: A Randomized Phase 3 Study on M…

Feat. D. Sallman
04:48
EHA 2022 Conference Coverage

EHA 2022 Magrolimab in Combination With Azacitidine for Untreated Hi…

Feat. D. Sallman
31
EHA 2022 Conference Coverage

Lecture Summary - EHA 2022 Magrolimab in Combination With Azacitidin…

Feat. D. Sallman
06:43
EHA 2022 Conference Coverage

EHA 2022 Magrolimab in Combination With Azacitidine for Untreated HR…

Feat. U. Platzbecker